Safety and Efficacy Study of rEV131 in the Treatment of Ocular Inflammation After Cataract Surgery



Status:Recruiting
Conditions:Ocular
Therapuetic Areas:Ophthalmology
Healthy:No
Age Range:18 - Any
Updated:4/2/2016
Contact:Susan French, ORA Clinical Research & Development Inc.
Email:sfrench@oraclinical.com
Phone:978-685-8900

Use our guide to learn which trials are right for you!

A Multi-Center, Randomized, Double Masked, Placebo and Active Controlled, Parallel-Group Study Evaluating the Safety and Efficacy of rEV131 2.5 Mg/mL, rEV131 1.25 Mg/mL, rEV131 0.625 Mg/mL, for the Treatment of Ocular Inflammation After Cataract Surgery

The purpose of this study is to evaluate the safety and effectiveness of three
concentrations of rEV131, a new investigational anti-inflammatory agent, compared to placebo
(an inactive substance) and an FDA approved anti-inflammatory agent in patients with ocular
inflammation who have undergone cataract extraction with intra-ocular lens implantation.


Inclusion Criteria:

- be male or female who has undergone unilateral cataract extraction by
phacoemulsification (PHACO) method with implantation of a posterior chamber
intraocular lens

Exclusion Criteria:

- have unstable glaucoma

- have an active bacterial and/or viral infection

- use any ocular or systemic anti-inflammatory agents within 1 week prior to enrollment
and for the duration of the study.
We found this trial at
1
site
300 Brickstone Square
North Andover, Massachusetts 01845
?
mi
from
North Andover, MA
Click here to add this to my saved trials